Porownywarka

Ziconotide vs Pentadecapeptide side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

ZiconotidePentadecapeptide

Udostępnij porównanie peptydów

Wlasciwosc	Ziconotide	Pentadecapeptide
Kategoria	Regeneracja	Regeneracja
Znany tez jako	Prialt, SNX-111	BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA Approved - Severe chronic pain Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Chronic pain management, neuropathic pain	Tissue healing, gut health, injury recovery
Jak dziala	Ziconotide is described as a synthetic form of omega-conotoxin MVIIA, a 25-amino-acid peptide originally associated with Conus magus venom. The source states that it inhibits N-type voltage-gated calcium channels in the spinal dorsal horn, which can reduce release of pain-related neurotransmitters. Limited blood-brain barrier penetration is given as the reason the evidence describes intrathecal rather than systemic administration.	Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.
Typowe dawkowanie	Limited community data available · See research protocols	Limited community data available · See research protocols
Dawkowanie z badań	0.1-19.2 mcg/day intrathecal · Chronic use via intrathecal pump · Intrathecal infusion only	250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection
Typowy czas trwania	Chronic use via intrathecal pump	4-12 weeks typical
Podanie	Intrathecal infusion only	Subcutaneous injection
Timing	Morning or as directed With or without food	Morning and evening; sometimes aligned with injury-related activity timing With or without food
Poziom dowodów	Zatwierdzone przez FDA	Przedkliniczne
Mozliwe skutki uboczne	Dizziness (Source reports dizziness and includes a 40% figure.) Nausea Confusion (Source includes confusion among notable neurologic adverse effects.) +6 więcej Hallucinations (Source links hallucinations to serious psychiatric risk.) Depression Suicidal ideation (Source includes suicidal thoughts among serious psychiatric concerns.) Memory impairment (Source reports memory problems as part of the adverse-effect profile.) Severe psychiatric symptoms (Source flags a black box warning and notes contraindication in people with a history of psychosis.) Intrathecal-only administration risk context (Source identifies Prialt as FDA approved and intrathecal only.)	Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.) Nausea (Reported side effect in the source.) Dizziness (Reported side effect in the source.) +1 więcej Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)
Podsumowanie researchu	The source characterizes ziconotide as an established drug rather than an early-stage research peptide, reporting FDA approval as Prialt in 2004 and European Commission approval in 2005. It describes use in severe chronic pain when intrathecal therapy is needed and other options are not tolerated or are inadequate. The source also notes a non-opioid profile with no reported tolerance or physical dependence signal in that summary, while emphasizing a narrow therapeutic window and important neuropsychiatric risks. Listed concerns include dizziness, confusion, memory impairment, gait instability, hallucinations, suicidal thoughts, and contraindication in people with a history of psychosis.	The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.
Referencje	Peptibase peptides Peptibase peptides +2 więcej Peptibase peptides Peptibase peptides	Źródło Źródło +3 więcej Źródło Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Ziconotide

Pentadecapeptide

Kategoria

Regeneracja

Znany tez jako

Prialt, SNX-111

BPC-157 Full Sequence, Stable Gastric Pentadecapeptide

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA Approved - Severe chronic pain

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Chronic pain management, neuropathic pain

Tissue healing, gut health, injury recovery

Jak dziala

Ziconotide is described as a synthetic form of omega-conotoxin MVIIA, a 25-amino-acid peptide originally associated with Conus magus venom. The source states that it inhibits N-type voltage-gated calcium channels in the spinal dorsal horn, which can reduce release of pain-related neurotransmitters. Limited blood-brain barrier penetration is given as the reason the evidence describes intrathecal rather than systemic administration.

Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.

Typowe dawkowanie

Limited community data available · See research protocols

Dawkowanie z badań

0.1-19.2 mcg/day intrathecal · Chronic use via intrathecal pump · Intrathecal infusion only

250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection

Typowy czas trwania

Chronic use via intrathecal pump

4-12 weeks typical

Podanie

Intrathecal infusion only

Subcutaneous injection

Timing

Morning or as directed

With or without food

Morning and evening; sometimes aligned with injury-related activity timing

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Przedkliniczne

Mozliwe skutki uboczne

Dizziness (Source reports dizziness and includes a 40% figure.)
Nausea
Confusion (Source includes confusion among notable neurologic adverse effects.)

+6 więcej

Hallucinations (Source links hallucinations to serious psychiatric risk.)
Depression
Suicidal ideation (Source includes suicidal thoughts among serious psychiatric concerns.)
Memory impairment (Source reports memory problems as part of the adverse-effect profile.)
Severe psychiatric symptoms (Source flags a black box warning and notes contraindication in people with a history of psychosis.)
Intrathecal-only administration risk context (Source identifies Prialt as FDA approved and intrathecal only.)

Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.)
Nausea (Reported side effect in the source.)
Dizziness (Reported side effect in the source.)

+1 więcej

Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)

Podsumowanie researchu

The source characterizes ziconotide as an established drug rather than an early-stage research peptide, reporting FDA approval as Prialt in 2004 and European Commission approval in 2005. It describes use in severe chronic pain when intrathecal therapy is needed and other options are not tolerated or are inadequate. The source also notes a non-opioid profile with no reported tolerance or physical dependence signal in that summary, while emphasizing a narrow therapeutic window and important neuropsychiatric risks. Listed concerns include dizziness, confusion, memory impairment, gait instability, hallucinations, suicidal thoughts, and contraindication in people with a history of psychosis.

The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.

Referencje

Peptibase peptides Peptibase peptides

+2 więcej

Peptibase peptides Peptibase peptides

Źródło Źródło

+3 więcej

Źródło Źródło Źródło

Pełny profil

Zobacz szczegóły